Updates
** Shares of medical equipment maker West Pharmaceuticals WST.N fall 3.7% to $210.19 in morning trade
** Company expects its HVP components business to grow mid-single digits instead of mid-to-high single digits, as it previously forecast
** Forecast cut came as one of WST's customers switched the type of component they were purchasing, which can currently only be supplied from one manufacturing facility, while the previous one could be sourced from multiple facilities
** This results in some stock-outs / delay in shipping this product to the customer - Nephron Research
** The business includes products to improve shelf life of packaged drugs, among others
** Company raised its annual adj EPS forecast to $6.15 to $6.35, up from $6 to $6.20
** WST reports Q1 adj. profit of $1.45/share, vs analysts' estimate of $1.23/share
** As of last close, WST stock down 33.4% YTD
(Reporting by Padmanabhan Ananthan and Puyaan Singh)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。